Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively manage motor and non-motor complications in advanced Parkinson's disease (PD). Healthcare costs, quality of life (QoL), effectiveness, and tolerability were assessed in routine care treatment with LCIG.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Parkinsonism Relat. Disord.

Title: Parkinsonism & related disorders

Publisher: Elsevier BV

ISSN (Electronic): 1873-5126

ISSN (Print): 1353-8020

Publication date (Electronic): Aug 2016

Volume: 29

Affiliations

[1 ] Department of Neurology, Karolinska University Hospital, Stockholm, Sweden. Electronic address: sven.palhagen@karolinska.se.

[2 ] Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.

[3 ] Department of Neuroscience, Neurology, Uppsala University, Sweden.

[4 ] Department of Clinical Neuroscience, Sahlgrenska University Hospital, Gothenburg, Sweden.

[5 ] Department of Neurology, Skane University Hospital, Lund, Sweden.

[6 ] Department of Neurology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.

[7 ] Department of Neurology, Neurocentre Norrlands University Hospital, Umeå, Sweden.

[8 ] Department of Neurology, Molde Hospital HNR, Molde, Norway.

[9 ] Department of Geriatric Medicine and Rehabilitation, Sundsvall Hospital, Sundsvall, Sweden.

[10 ] AbbVie Inc., USA.

[11 ] AbbVie AB, Sweden.

Article

Publisher Item ID: S1353-8020(16)30198-5

DOI: 10.1016/j.parkreldis.2016.06.002

PubMed ID: 27318707

SO-VID: c891d31f-98f4-438c-a7d6-60b25ac355e5

History

Keywords: Cost,Infusion,Parkinson’s disease,Levodopa,LCIG

Data availability:

Keywords: Cost, Infusion, Parkinson’s disease, Levodopa, LCIG

Comments

Comment on this article

scite_

Cited by 24

See all cited by